



Trendlines Group’s Rights Issue Oversubscribed, Showcasing Investor Confidence

- Rights issue of approximately S\$3.9 million oversubscribed by approximately 25%.
- Proceeds to strengthen financial position and support portfolio companies.

Misgav, Israel and Singapore, 20 August 2025 – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”), the Israel- and Singapore-based company focused on building value through innovation-based medical and agrifood technologies, today announced that its rights issue to raise approximately S\$3.9 million has been oversubscribed by approximately 25%. Investors applied for an excess of 34 million rights shares, against the 137 million rights shares available, reflecting strong confidence in Trendlines’ long-term strategy and growth potential.

The funds will be deployed to support the Company’s business by financing direct and indirect investments into existing portfolio companies, including supporting exit strategies where appropriate, and to meet general working capital needs.

Management Commentary

Commenting on the rights issue, Haim Brosh, Trendlines’ Chief Executive Officer, said, “The strong oversubscription of our rights issue is a clear signal of investor confidence in Trendlines’ vision and strategy. With this additional capital, we can provide crucial support to our portfolio companies, help drive successful exits, and unlock long-term value for our shareholders. With an oversubscription of 25%, we are delighted with the outcome of the rights issue, marked by the participation of our major shareholders, a clear demonstration of their continued confidence in the Company, its vision, and its future growth.”

END

About The Trendlines Group Ltd.

Trendlines establishes, funds, and incubates innovation-based medical and agrifood technologies. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock



Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore:

Kamal Samuel, Financial PR

kamal@financialpr.com.sg

Rishika Tiwari, Financial PR

rishika@financialpr.com.sg

Tel: +65.6438.2990